What is ProSciento?
ProSciento, Inc. operates as a high-precision clinical research organization (CRO) dedicated to the metabolic disease sector. By providing a comprehensive suite of services—ranging from regulatory affairs and scientific consulting to data management and patient recruitment—the company serves as a critical partner for pharmaceutical and biotech entities. Formerly known as Profil Institute for Clinical Research, the organization has evolved into a specialized hub for clinical development, leveraging deep domain expertise to navigate the rigorous regulatory and scientific requirements inherent in metabolic health trials. Its market position is defined by its ability to integrate statistical rigor with operational excellence in patient-centric research environments.
How much funding has ProSciento raised?
ProSciento has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in ProSciento
PPP
Public-Private Partnership
What's next for ProSciento?
With the support of its recent capital allocation, ProSciento is positioned to scale its clinical development infrastructure and enhance its data management capabilities. The current enterprise-level funding trajectory suggests a strategic pivot toward expanding its footprint in the NAFLD/NASH therapeutic space, where demand for specialized clinical oversight is accelerating. Future growth will likely focus on integrating advanced statistical modeling and quality compliance frameworks to maintain its competitive edge. By optimizing its recruitment services and scientific monitoring protocols, the firm aims to shorten the development lifecycle for its partners, thereby reinforcing its status as a premier CRO in the metabolic research ecosystem.
See full ProSciento company page
